文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

目前针对银屑病和银屑病关节炎的药理学治疗指南。

Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis.

机构信息

a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.

b Department of Pathology , Wake Forest School of Medicine , Winston-Salem , NC , USA.

出版信息

Expert Rev Clin Pharmacol. 2018 Dec;11(12):1209-1218. doi: 10.1080/17512433.2018.1548277. Epub 2018 Dec 4.


DOI:10.1080/17512433.2018.1548277
PMID:30449211
Abstract

Psoriasis is a common chronic skin condition that is prevalent worldwide. Despite the numerous treatment options available, discrepancies exist between international guidelines. Areas covered: This review aims to evaluate the current international guidelines for the systemic treatment of psoriasis and psoriatic arthritis. Expert commentary: Most guidelines are unanimous on medication dosing and laboratory monitoring. However, even the most up-to-date guidelines do not include many of the new biologic medications. Guidelines will require frequent updates to include the newer treatments and will soon need to state a recommendation on the use of biosimilars.

摘要

银屑病是一种常见的慢性皮肤病,在世界各地都很普遍。尽管有许多治疗选择,但国际指南之间存在差异。 涵盖领域: 本篇综述旨在评估当前用于治疗银屑病和银屑病关节炎的全身性治疗的国际指南。 专家评论: 大多数指南在药物剂量和实验室监测方面是一致的。 然而,即使是最新的指南也没有包括许多新的生物制剂药物。 指南将需要频繁更新以纳入新的治疗方法,并很快需要就生物类似药的使用提出建议。

相似文献

[1]
Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis.

Expert Rev Clin Pharmacol. 2018-12-4

[2]
Biosimilars in psoriasis: the future or not?

Cutis. 2017-2

[3]
Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.

J Eur Acad Dermatol Venereol. 2010-9-14

[4]
Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.

BioDrugs. 2013-8

[5]
Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.

Curr Pharm Des. 2014

[6]
Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: a systematic review.

J Rheumatol. 2014-11

[7]
Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.

Curr Rheumatol Rev. 2019

[8]
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.

Rheumatol Int. 2016-5

[9]
Combination therapy of biologics with traditional agents in psoriasis.

Skin Therapy Lett. 2011-6

[10]
Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP).

J Eur Acad Dermatol Venereol. 2018-11-28

引用本文的文献

[1]
FGF7 as an essential mediator for the onset of ankylosing enthesitis related to psoriatic dermatitis.

Life Sci Alliance. 2025-2-7

[2]
Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions.

Therap Adv Gastroenterol. 2025-1-2

[3]
A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis.

Front Immunol. 2023

[4]
Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics.

Pharmaceuticals (Basel). 2022-9-3

[5]
Erythema Increase Predicts Psoriasis Improvement after Phototherapy.

J Clin Med. 2021-8-30

[6]
Optical control of adenosine A receptor function in psoriasis.

Pharmacol Res. 2021-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索